Markt für pharmazeutische Zwischenprodukte – Erkenntnisse aus globaler und regionaler Analyse – Prognose bis 2031

  • Report Code : TIPRE00005559
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 185
Buy Now

Der Markt für pharmazeutische Zwischenprodukte wird im Jahr 2028 voraussichtlich 37.290,33 Millionen US-Dollar erreichen, verglichen mit 27.356,70 Millionen US-Dollar im Jahr 2020. Es wird geschätzt, dass der Markt von 2021 bis 2028 mit einer jährlichen Wachstumsrate von 4,2 % wächst.



Die Der Markt für pharmazeutische Zwischenprodukte wurde auf der Grundlage von Typ, Anwendung, Vertriebskanal und Region analysiert. Der regionale Markt ist in Nordamerika, Europa, den asiatisch-pazifischen Raum, den Nahen Osten und Afrika sowie Süd- und Mittelamerika unterteilt. Der Bericht legt den Schwerpunkt auf Parameter wie Markttrends, technologische Fortschritte, Marktdynamik und die Analyse der Wettbewerbslandschaft führender Unternehmen, um Einblicke und eine eingehende Analyse des Marktes für pharmazeutische Zwischenprodukte zu bieten. Es umfasst auch die Analyse der COVID-19-Pandemie im gesamten Markt in allen Schlüsselregionen.



Lukrative Regionen für den Markt für pharmazeutische Zwischenprodukte



Markteinblicke



Steigende Prävalenz chronischer Krankheiten und Infektionskrankheiten



< p>Pharmazeutische Zwischenprodukte sind die Bausteine für pharmazeutische Wirkstoffe (APIs). Hierbei handelt es sich um Rohstoffe, die bei der Massenproduktion von Arzneimitteln einer molekularen Veränderung oder Verarbeitung unterliegen. Daher steigt der Bedarf an pharmazeutischen Zwischenprodukten mit der steigenden Nachfrage nach Medikamenten zur Behandlung chronischer Krankheiten. Nach Angaben der Centers for Disease Control and Prevention (CDC) leiden 6 von 10 Erwachsenen in den USA an mindestens einer chronischen Krankheit wie Krebs, Herzerkrankungen, Lungenerkrankungen, Schlaganfall, neurologischen Erkrankungen, Diabetes und Nierenerkrankungen. Darüber hinaus leiden 4 von 10 Erwachsenen im Land an zwei oder mehr chronischen Krankheiten. Darüber hinaus starben laut Pressemitteilung der European Chronic Disease Alliance (ECDA) im Jahr 2014 neun von zehn Menschen in Europa an chronischen Krankheiten. Somit werden 70–80 % der gesamten Gesundheitskosten für die Behandlung chronischer Krankheiten aufgewendet.



Die zunehmende Prävalenz von Infektionskrankheiten, insbesondere in Südostasien, dürfte in den kommenden Jahren auch die Nachfrage nach APIs ankurbeln und letztendlich das Wachstum des Marktes für pharmazeutische Zwischenprodukte vorantreiben. Beispielsweise starben laut dem Revised National Tuberculosis Control Program Report im Jahr 2018 in Indien etwa 4,4 Lakh-Patienten an Tuberkulose, das sind 29 % der insgesamt 1,5 Millionen durch die Krankheit verursachten Todesfälle weltweit. Daher steigert die hohe Prävalenz chronischer Krankheiten und Infektionskrankheiten die Nachfrage nach Arzneimitteln und unterstreicht schließlich den Bedarf an pharmazeutischen Zwischenprodukten.



Typbasierte Einblicke



Der Markt für pharmazeutische Zwischenprodukte, von Typ, ist in GMP und Nicht-GMP unterteilt. Das GMP-Segment hatte im Jahr 2020 den größten Marktanteil, während dasselbe Segment im Prognosezeitraum voraussichtlich die höchste CAGR von 4,4 % im Markt verzeichnen wird.




Markt für pharmazeutische Zwischenprodukte, nach Typ – 2020 und 2028



Anwendungsbasierte Erkenntnisse



Der Markt für pharmazeutische Zwischenprodukte ist nach Anwendung in Antibiotika, fiebersenkende Analgetika, Vitamine und andere unterteilt Andere. Das Antibiotika-Segment hielt im Jahr 2020 den größten Marktanteil. Außerdem wird erwartet, dass dieses Segment im Prognosezeitraum die höchste CAGR von 4,9 % auf dem Markt verzeichnen wird.




Vertriebskanalbasierte Einblicke



Auf der Grundlage des Vertriebskanals wurde der Markt für pharmazeutische Zwischenprodukte in Vertriebs- und Direktvertrieb unterteilt. Das Direktvertriebssegment hatte im Jahr 2020 den größten Marktanteil und das Vertriebssegment verzeichnete im Prognosezeitraum schätzungsweise die höchste CAGR von 4,2 % auf dem Markt.



Strategische Einblicke



Unternehmen, die auf dem Markt für pharmazeutische Zwischenprodukte tätig sind, verfolgen organische Strategien wie Produkteinführungen und -erweiterungen, um ihre Präsenz und ihr Produktportfolio weltweit zu erweitern und den wachsenden Anforderungen gerecht zu werden.



Nach Typ



  • GMP

  • Nicht-GMP


Nach Anwendung




  • Antibiotika

  • Antipyretische Analgetika
  • Vitamine

  • Andere


Nach Vertriebskanal




  • Vertriebspartner

  • Direktvertrieb

Nach Geografie




  • Nordamerika

    • USA

    • Kanada

    • Mexiko


  • Europa

    • Deutschland

    • Frankreich

    • Italien

    • Vereinigtes Königreich
    • Spanien

    • Schweiz

    • Belgien

    • Griechenland

    • Norwegen

    • Portugal

    • Schweden

    • Tschechische Republik

    • Kroatien

    • Irland

    • Dänemark

    • Niederlande

    • Russland< /li>
    • Restliches Europa



  • Asien-Pazifik (APAC)

    • China

    • Indien
    • Südkorea

    • Japan

    • Australien

    • Rest von APAC



  • Naher Osten und Afrika (MEA). )

    • Südafrika

    • Saudi-Arabien

    • VAE

    • Türkei

    • Rest von MEA

    • Süd- und Mittelamerika (SCAM)

      • Brasilien

      • Argentinien

      • Rest von SCAM

      < /li>

    Unternehmensprofile




    • Pfizer, Inc

    • Dishman Group

    • Dextra Laboratories Limited
    • Sanofi Winthrop Industries SA

    • Vertellus Holdings LLC

    • BASF SE

    • Lianhetech

    • Codexis

    • Midas Pharma GmbH

    • Chiracon GmbH

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are the driving factors for the Pharmaceutical Intermediates market across the globe?

Key factors that are driving the market are to rising prevalence of chronic diseases and infectious diseases, and escalating investment by pharmaceutical companies in R&D activities. However, high cost of drug manufacturing hinders the market growth.

What are Pharmaceutical Intermediates?

Pharmaceutical intermediates are the raw materials used to manufacture active pharmaceutical ingredients for the final drug formulation. Pharmaceutical intermediates are used in the production of bulk drugs as well as for research and development purpose by various pharm and biopharma companies. Pharmaceutical intermediates are formed at the time of process of production or synthesis of active pharmaceutical ingredients.

What is the cost of Pharmaceutical Intermediates?

The costs of the Pharmaceutical Intermediates are much higher, and they may cost US$ 5–50, or more, per kgs. The cost may also differ from product to product types.

The List of Companies - Pharmaceutical Intermediate Market

  1. Pfizer Inc.
  2. Sanofi
  3. BASF SE
  4. Lianhe Chemical Technology Co., Ltd
  5. Dishman Carbogen Amcis Ltd
  6. Codexis
  7. Midas Pharma GmbH
  8. chiracon GmbH
  9. Dextra Laboratories Limited
  10. Vertellus Holdings LLC

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports